stoxline Quote Chart Rank Option Currency Glossary
  
PolyPid Ltd. (PYPD)
4.07  0.05 (1.24%)    07-11 16:00
Open: 4
High: 4.1
Volume: 4,182
  
Pre. Close: 4.02
Low: 4
Market Cap: 7(M)
Technical analysis
2024-07-12 12:52:45 PM
Short term     
Mid term     
Targets 6-month :  4.91 1-year :  5.24
Resists First :  4.2 Second :  4.48
Pivot price 4.06
Supports First :  3.75 Second :  3.12
MAs MA(5) :  4.01 MA(20) :  4.1
MA(100) :  4.68 MA(250) :  5.77
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  37.8 D(3) :  35.4
RSI RSI(14): 45.8
52-week High :  12 Low :  3.56
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ PYPD ] has closed below upper band by 49.7%. Bollinger Bands are 50.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.37 - 4.39 4.39 - 4.41
Low: 3.97 - 4 4 - 4.02
Close: 3.99 - 4.02 4.02 - 4.05
Company Description

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Headline News

Tue, 02 Jul 2024
PolyPid Revamps Share Option Plan for Stakeholders - TipRanks

Mon, 10 Jun 2024
PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company’s Ongoing D-PLEX₁₀₀ Phase 3 Trial - Yahoo Finance

Wed, 28 Feb 2024
PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference - GlobeNewswire

Thu, 18 Nov 2021
PolyPid Announces 500th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ in Abdominal Surgery - GlobeNewswire

Tue, 21 Jul 2020
PolyPid (PYPD) Stock Price, News & Analysis - MarketBeat

Wed, 01 Jul 2020
PolyPid Initiates First Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Post-Abdominal Surgery Incisional Infections - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 5 (M)
Shares Float 2 (M)
Held by Insiders 30 (%)
Held by Institutions 39.2 (%)
Shares Short 5 (K)
Shares Short P.Month 5 (K)
Stock Financials
EPS -9.9
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.49
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -51.2 %
Return on Equity (ttm) -261.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -4.49
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -0.42
PEG Ratio 0
Price to Book value 2.73
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android